 phase II evalu menogaril cisplatin-refractori advanc ovarian carcinoma collabor trial north central cancer treatment group mayo clinic women advanc recurr epitheli ovarian carcinoma prior chemotherapi platinum-bas regimen menogaril week phase II trial partial respons measur diseas patient nonmeasur evalu patient overal object respons rate confid interv median time progress patient month median surviv month toxic accept leukopenia gastrointestin toxic twenty-nin percent patient venou irrit pain phlebiti intraven inject site menogaril protocol modest antineoplast activ ovarian carcinoma patient respons short durat surviv advantag menogaril treatment